News Search Results
Mar 20, 2025, 05:00 ET EndoArt Inventor Dr. Ofer Daphna to Deliver Keynote Lecture at World Cornea Congress 2025
transforming corneal care and expanding accessibility to innovative treatments worldwide. This keynote lecture comes at a pivotal moment in ophthalmology, as the field continues to embrace cutting-edge solutions for corneal diseases. With the growing demand for innovative, EndoArt stands at the forefront
More news about: EyeYon Medical
Mar 20, 2025, 05:00 ET EndoArt Inventor Dr. Ofer Daphna to Deliver Keynote Lecture at World Cornea Congress 2025
transforming corneal care and expanding accessibility to innovative treatments worldwide. This keynote lecture comes at a pivotal moment in ophthalmology, as the field continues to embrace cutting-edge solutions for corneal diseases. With the growing demand for innovative, EndoArt stands at the forefront
More news about: EyeYon Medical
Mar 19, 2025, 12:48 ET Glaucoma Research Foundation Announces the 2025 Shaffer Grants for Innovative Glaucoma Research
of MedicineProject: Impact of Low Blood Pressure on ONH Biomechanics in Glaucoma The Larry Haimovitch Grant for Innovation in OphthalmologyShruthi Karnam, PhDUniversity of California, BerkeleyProject:
More news about: Glaucoma Research Foundation
Mar 19, 2025, 08:07 ET SAMS Completes Life-Saving Ramadan Medical Mission in Syria, Delivering Critical Care and Training to Hundreds
specialized training sessions for 916 local healthcare workers. Working across specialties such as interventional cardiology, oncology, nephrology, ophthalmology, pediatrics, and maternal health, the team provided expert care—free of charge—to patients who otherwise had no access to specialized treatments.
More news about: SAMS
Mar 19, 2025, 07:23 ET U.S. News & World Report Names 64 AMSURG Ambulatory Surgery Centers Among Best in Nation
outcomes; risk-adjustment and more. Ambulatory Surgery Centers were evaluated in four separate specialty areas: Gastroenterology, Orthopedics, Ophthalmology and Urology. AMSURG centers were recognized in all four specialty areas. To learn more about AMSURG's award-winning centers or to find one
More news about: AMSURG Corporation
Mar 18, 2025, 20:55 ET Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce
More news about: Innovent Biologics
Mar 18, 2025, 12:00 ET MemorialCare Named Best Ambulatory Surgery Centers in U.S. News & World Report Second Year in a Row
U.S. News & World Report rated nearly 4,300 surgery centers in three separate specialty areas: Colonoscopy & Endoscopy, Ophthalmology, and Orthopedics & Spine FOUNTAIN VALLEY, Calif.,
More news about: MemorialCare Medical Foundation
Mar 18, 2025, 09:00 ET Bloomage Passes GMP Audit by South Korea's MFDS, Strengthening its Global Quality Assurance
Bloomage is now positioned to provide GMP-certified pharmaceutical-grade Sodium Hyaluronate (Hyatrue®) to Korean pharmaceutical manufacturers of ophthalmology, orthopedics, aesthetic medicines, and regenerative medicines, covering Eyedrops, intra-articular injections, dermal fillers, mesotherapy solutions tissue
More news about: Bloomage
Mar 18, 2025, 08:00 ET SIFI announces collaboration with the University of California, San Francisco on Acanthamoeba Keratitis
March 18, 2025 /PRNewswire/ -- SIFI, a leading international pharmaceutical company specializing in ophthalmology, is pleased to announce a scientific collaboration with the University of California, San Francisco ("UCSF") aimed at
More news about: SIFI S.p.A.
Mar 18, 2025, 04:00 ET Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio. We look forward
More news about: Formosa Pharmaceuticals Inc.,
Mar 18, 2025, 00:01 ET U.S. News & World Report Releases Second Annual Best Ambulatory Surgery Centers Ratings
Ophthalmology,
More news about: U.S. News & World Report, L.P.
Mar 17, 2025, 08:19 ET WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer, cardiovascular disease, ophthalmology, rheumatology, central nervous system, medical aesthetics and rare tumors, etc.).
More news about: WuXi AppTec
Mar 14, 2025, 04:35 ET China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
SYCUME® has brought together the expertise of leading ophthalmology and endocrinology specialists. The approval of SYCUME® not only highlights Innovent's innovative R&D capabilities in the fields of ophthalmology and endocrinology but also reflects the high recognition of this
More news about: Innovent Biologics
Mar 14, 2025, 04:35 ET 中國首個IGF-1R單抗：信達生物信必敏®獲批，填補甲狀腺眼病治療空白
1. Bartley G. The epidemiological characteristics and clinical course of ophthalmology associated with autoimmune thyroid disease in Olmsted Country, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588.
More news about: 信達生物
Mar 13, 2025, 16:05 ET REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
delivery of sura-vec in patients with bilateral wet AMD is complete. Positive results from this study were presented at the 2024 American Academy of Ophthalmology annual meeting, supporting the potential of sura-vec to treat bilateral disease at an expected commercial launch
More news about: REGENXBIO Inc.
Mar 13, 2025, 07:23 ET AMSURG Introduces New Company Values to Strengthen Culture and Commitment to Excellence
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. With a focus on strategic growth and innovation, AMSURG is committed to transforming the future of ambulatory surgery center care
More news about: AMSURG Corporation
Mar 13, 2025, 07:00 ET SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
who are in desperate need for a therapy. I am immensely proud of our outstanding team at SpliceBio whose depth of experience in leading numerous ophthalmology gene therapy trials in the last 15 years is unparalleled." Paul Yang, M.D., Ph.D., Chief of the Paul H. Casey Ophthalmic Genetics
More news about: SpliceBio
Mar 13, 2025, 06:31 ET Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides 2025 Guidance
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Mar 13, 2025, 06:30 ET Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
Mar 12, 2025, 19:30 ET STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Mar 12, 2025, 10:01 ET Clinical Trial Services Market worth US$101.86 billion by 2030 with 8.9% CAGR | MarketsandMarkets™
system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas. The oncology segment accounted for the largest share
More news about: MarketsandMarkets
Mar 11, 2025, 13:01 ET Lions KidSight USA Program Recognized as 'Champion for Vision' by the Children's Eye Foundation of the American Association for Pediatric Ophthalmology and Strabismus
(KidSight), a program of Lions International, was recognized with the Champion for Vision award at the annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting in Salt Lake City, Utah, last week.
More news about: Lions International
Mar 11, 2025, 12:54 ET Laser Locators Champions Sustainability in Ophthalmic Equipment
impact. A Future of Sustainable Ophthalmology As sustainability becomes a top priority in the ophthalmic industry, Laser Locators remains committed to reducing waste, cutting costs, and expanding access to high-quality equipment. "Sustainability in ophthalmology isn't just about reducing waste—it's
More news about: Laser Locators
Mar 11, 2025, 12:10 ET Top Oculofacial Plastic Surgeons Announce the Grand Opening of AestheticEye Oculoplastic Surgeons, a new Aesthetic Surgery Practice Serving the Cincinnati and Dayton Areas
Miami University and the University of Cincinnati College of Medicine, Dr. Henson completed her ophthalmology residency at the renowned Bascom Palmer Eye Institute in Miami, Florida. She further honed her expertise during
More news about: AestheticEye Oculoplastic Surgeons
Mar 10, 2025, 16:30 ET Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc